Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 11:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: alone Clear all
Completed Phase 2 Interventional Results available

Evaluation of Dupilumab's Effects on Airway Inflammation in Patients With Asthma

NCT02573233
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Dupilumab SAR231893/REGN668, fluticasone propionate and salmeterol, budesonide and formoterol, mometasone furoate and formoterol
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
6
States / cities
Tucson, Arizona • Denver, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2022 · Synced Sep 12, 2026, 11:06 AM EDT
Recruiting Not applicable Interventional

Wearable Device and Behavioral Support for Enhancing Arm Use After Stroke

NCT07042152
View directory record Official record
Conditions
Chronic Stroke Patients
Interventions
Smartwatch App for Movement Variability, Smartwatch App for Active Time, Motivational Interviewing (Within Subjects)
Other · Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 84 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2025 · Synced Sep 12, 2026, 11:06 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma

NCT07085338
View directory record Official record
Conditions
Neuroblastoma Recurrent
Interventions
Temozolomide, Irinotecan, hu14.18K322A, N803, Sargramostim
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 30 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
San Francisco, California • Aurora, Colorado • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Phase 1Phase 2 Interventional

Dose-escalation Study of a Contrast Agent for Delineation of Urological Anatomy in Minimally Invasive Surgery

NCT03106038
View directory record Official record
Conditions
Intraoperative Ureter Injury
Interventions
Nerindocianine for Injection
Drug
Lead sponsor
Li-Cor, Inc.
Industry
Eligibility
19 Years and older · Female only
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced Sep 12, 2026, 11:06 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety and Efficacy of Perioperative Remodulin® in Orthotopic Liver Transplant Recipients

NCT01884038
View directory record Official record
Conditions
Liver Transplant
Interventions
treprostinil sodium, Placebo
Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 12, 2026, 11:06 AM EDT
Recruiting Not applicable Interventional

Trial of Latex Vs Non-latex Hemorrhoid Banding

NCT06625138
View directory record Official record
Conditions
Hemorrhoid, Hemorrhoid Bleeding
Interventions
Latex Band, Non-Latex Band
Device
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 12, 2026, 11:06 AM EDT
Terminated Phase 2 Interventional Results available

A Study Of The Safety And Efficacy Of PF-04191834 In Patients With Osteoarthritis Of The Knee

NCT01147458
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
PF-04191834, PF-04191834 placebo, Naproxen placebo, Naproxen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
25
States / cities
Peoria, Arizona • Phoenix, Arizona • Anaheim, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2013 · Synced Sep 12, 2026, 11:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mucin Levels in Dry Eye and Normal Populations

NCT05911555
View directory record Official record
Conditions
Dry Eye
Interventions
Not listed
Lead sponsor
ORA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

NCT01372826
View directory record Official record
Conditions
Renal Impairment
Interventions
NKTR118 Group1, NKTR118 Group 2, NKTR118 Group3, NKTR118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
3
States / cities
Anaheim, California • Orlando, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Sep 12, 2026, 11:06 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Food DNA Digestion

NCT06687226
View directory record Official record
Conditions
Digestion Rate
Interventions
Reconstitutable food powder
Dietary Supplement
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 12, 2026, 11:06 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

NCT04140526
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Phase 2 Interventional Results available

Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients

NCT00354978
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Leucovorin, Irinotecan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2011 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Drug-Drug Interaction Between Colchicine and Ritonavir

NCT00983515
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Colchicine, Ritonavir
Drug
Lead sponsor
Mutual Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
East Grand Forks, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2009 · Synced Sep 12, 2026, 11:06 AM EDT
Active, not recruiting Phase 1 Interventional

A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab in PIK3CA-Mutated Cancers

NCT06496568
View directory record Official record
Conditions
PIK3CA-Mutated Cancers
Interventions
Inavolisib, Atezolizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of a Drug Delivery System in Glaucoma

NCT01016691
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
High Dose Drug Device, Low Dose Drug Device, Placebo Device, bimatoprost 0.03%
Drug
Lead sponsor
Vistakon Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Miami, Florida • Philadelphia, Pennsylvania • Mt. Pleasant, South Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Phase 1Phase 2 Interventional

Vaccination With Flt3L, Radiation, and Poly-ICLC

NCT03789097
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Head and Neck Squamous Cell Carcinoma
Interventions
Pembrolizumab, Flt3L, Radiation, Poly ICLC
Drug · Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

NCT02093897
View directory record Official record
Conditions
Congenital Hemophilia A
Interventions
rVIII-SingleChain
Biological
Lead sponsor
CSL Behring
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 26, 2017 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

STI/HIV Intervention Behavioral Intervention Program

NCT04547413
View directory record Official record
Conditions
Sexually Transmitted Infections
Interventions
STI/HIV Intervention Behavioral Intervention Program
Behavioral
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 30 Years
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
2
States / cities
Fayetteville, North Carolina • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Phase 1Phase 2 Interventional

Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma Multiforme

NCT01260506
View directory record Official record
Conditions
Glioblastoma Multiforme
Interventions
VB-111, Bevacizumab
Drug
Lead sponsor
Vascular Biogenics Ltd. operating as VBL Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacology Study of VP 20629 in Adults With Friedreich's Ataxia

NCT01898884
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
VP 20629, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 45 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2021 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of a Topical Retinol on Epigenetic Changes and Expression of Certain Genes in the Skin Using Non-invasive Measurements

NCT06658847
View directory record Official record
Conditions
Retinoid, Skin Aging, Epigenomics
Interventions
Night Cream Usage, No Night Cream Usage
Other
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Phase 2 Interventional Results available

Extension Study of Protocol ENB-002-08 - Study of Asfotase Alfa in Infants and Young Children With Hypophosphatasia (HPP)

NCT01205152
View directory record Official record
Conditions
Hypophosphatasia
Interventions
asfotase alfa
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
24 Weeks to 42 Months
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
5
States / cities
Wilmington, Delaware • Springfield, Missouri • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Sep 12, 2026, 11:06 AM EDT
Completed Phase 1 Interventional Results available

An Open Label Study to Describe the Pharmacokinetics of Daptomycin in Infants

NCT00942149
View directory record Official record
Conditions
Sepsis
Interventions
Daptomycin
Drug
Lead sponsor
Duke University
Other
Eligibility
48 Hours to 120 Days
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Sep 12, 2026, 11:06 AM EDT
Terminated Not applicable Interventional Results available

Trial to Evaluate UltraSound in the Treatment of Tibial Fractures

NCT00667849
View directory record Official record
Conditions
Tibial Fractures
Interventions
Exogen 4000+, Sham
Device
Lead sponsor
Bioventus LLC
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
13
States / cities
San Francisco, California • Tampa, Florida • Indianapolis, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Sep 12, 2026, 11:06 AM EDT